Next results · Q4 2026Projected
10-K due Mar 8 – Apr 2
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 2 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 8 – Apr 2
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$4.55M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 2.7% either way
Up after 3 of 9, down after 6.
The stock’s move from the last close before each release to the first close after it, over the last 9 releases. Largest: −9.4% after Q4 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- 10-Q filed
- 44 to 45 days
- over its last 8
- 10-K filed
- 72 to 85 days
- over its last 2
Based on 2 prior 10-K filings.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR